Multidrug resistance in Cancer: Stratagem view and current challanges

Prof. Chiara Riganti,
Associate professor, MD,Department of Oncology, Torino, Italy ,

Prof. Javier De Las Rivas
Full Professor, PhD,Cancer Research Center, University of Salamanca, Salamanca, Spain

Dissecting the MDR with an European perspective: discovering STRATAGEM and PANDORA projects
Professor Chiara Riganti
Associate professor, MD, Department of Oncology, Torino, Italy

Computational biology for pharmacogenomics and OMICS data mining in MDR: a matter of networking
Professor Javier De Las Rivas
Full Professor, PhD, Cancer Research Center, University of Salamanca, Salamanca, Spain

Biological and pharmacological underpinnings of therapeutic resistance in pancreatic cancer
Professor Elisa Giovannetti
Laboratory of Medical Oncology, Medical University of Amsterdam, The Netherlands

A study within PANDORA Project: The Effects of Different Types of Calorie Restriction on miRNAs linked to Multiple Drug Resistance in Cancer
Professor Bilge Guvenc Tuna
Associate Professor, Department of Biophysics, Faculty of Medicine, Yeditepe University, Istanbul, Turkey

Efficacy versus safety: what is most important in MDR reversing agents?
Dr Yordan Yordanov
Research associate, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria

Novel approaches to overcoming resistance to immune checkpoint blockade
Dr Elisabeth Pérez-Ruiz
MD, Oncology Unit, Hospital Costa del Sol, Malaga, Spain